TearSolutions Advances Lacripep® for Neurotrophic Keratitis with FDA Designations and Phase 2 Trial Launch

As reported on Business Wire, TearSolutions, a clinical-stage biotechnology company focused on ophthalmic therapies, has announced key regulatory and clinical progress for its investigational drug Lacripep® in the treatment of…

Continue Reading TearSolutions Advances Lacripep® for Neurotrophic Keratitis with FDA Designations and Phase 2 Trial Launch